These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 24206058

  • 1. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
    Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, Shi H, Chines AA, Mirkin S.
    J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
    Abraham L, Bushmakin AG, Dragon E, Komm BS, Pinkerton JV.
    Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
    [Abstract] [Full Text] [Related]

  • 4. A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.
    Stevenson JC, Chines A, Pan K, Ryan KA, Mirkin S.
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2329-38. PubMed ID: 25894963
    [Abstract] [Full Text] [Related]

  • 5. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH.
    Menopause; 2009 Jun; 16(6):1116-24. PubMed ID: 19546826
    [Abstract] [Full Text] [Related]

  • 6. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV, Pickar JH, Racketa J, Mirkin S.
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [Abstract] [Full Text] [Related]

  • 7. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
    Skouby SO, Pan K, Thompson JR, Komm BS, Mirkin S.
    Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
    [Abstract] [Full Text] [Related]

  • 8. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH, Mirkin S.
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [Abstract] [Full Text] [Related]

  • 9. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
    Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH.
    Maturitas; 2009 Aug 20; 63(4):329-35. PubMed ID: 19647382
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
    Palacios S, Arias L, Lavenberg J, Pan K, Mirkin S, Komm BS.
    Climacteric; 2016 Jun 20; 19(3):261-7. PubMed ID: 26940720
    [Abstract] [Full Text] [Related]

  • 12. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
    Kagan R.
    J Womens Health (Larchmt); 2012 Sep 20; 21(9):975-81. PubMed ID: 22759213
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.
    Pinkerton JV, Bushmakin AG, Racketa J, Cappelleri JC, Chines AA, Mirkin S.
    Menopause; 2014 Mar 20; 21(3):243-51. PubMed ID: 23899830
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S, Currie H, Mikkola TS, Dragon E.
    Maturitas; 2015 Apr 20; 80(4):435-40. PubMed ID: 25684082
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
    Lobo RA, Pinkerton JV, Gass MLS, Dorin MH, Ronkin S, Pickar JH, Constantine G.
    Fertil Steril; 2009 Sep 20; 92(3):1025-1038. PubMed ID: 19635615
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
    Pickar JH, Lavenberg J, Pan K, Komm BS.
    Menopause; 2018 Mar 20; 25(3):273-285. PubMed ID: 29088019
    [Abstract] [Full Text] [Related]

  • 20. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G, Bobula J, Mirkin S.
    Climacteric; 2010 Apr 20; 13(2):132-40. PubMed ID: 19863455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.